- Home
- IOBT vs ALRN Comparison
IOBT vs ALRN Comparison
Compare IOBT & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- ALRN
- Stock Information
- Founded
- IOBT 2014
- ALRN 2001
- Country
- IOBT Denmark
- ALRN United States
- Employees
- IOBT N/A
- ALRN N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- ALRN Health Care
- Exchange
- IOBT Nasdaq
- ALRN Nasdaq
- Market Cap
- IOBT 81.7M
- ALRN 76.9M
- IPO Year
- IOBT 2021
- ALRN 2017
- Fundamental
- Price
- IOBT $0.89
- ALRN $3.42
- Analyst Decision
- IOBT Strong Buy
- ALRN Strong Buy
- Analyst Count
- IOBT 3
- ALRN 1
- Target Price
- IOBT $9.33
- ALRN $19.00
- AVG Volume (30 Days)
- IOBT 279.8K
- ALRN 93.8K
- Earning Date
- IOBT 11-12-2024
- ALRN 11-26-2024
- Dividend Yield
- IOBT N/A
- ALRN N/A
- EPS Growth
- IOBT N/A
- ALRN N/A
- EPS
- IOBT N/A
- ALRN N/A
- Revenue
- IOBT N/A
- ALRN N/A
- Revenue This Year
- IOBT N/A
- ALRN N/A
- Revenue Next Year
- IOBT N/A
- ALRN N/A
- P/E Ratio
- IOBT N/A
- ALRN N/A
- Revenue Growth
- IOBT N/A
- ALRN N/A
- 52 Week Low
- IOBT $0.73
- ALRN $1.57
- 52 Week High
- IOBT $2.10
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- IOBT 33.52
- ALRN 47.41
- Support Level
- IOBT $0.86
- ALRN $3.37
- Resistance Level
- IOBT $1.29
- ALRN $3.92
- Average True Range (ATR)
- IOBT 0.12
- ALRN 0.35
- MACD
- IOBT -0.04
- ALRN -0.06
- Stochastic Oscillator
- IOBT 7.15
- ALRN 21.36
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.